Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. covers events occurring between October 8, 2018, and October 29, 2018, with a report date of October 28, 2018. The filing primarily addresses unregistered sales of equity securities and the departure of a senior officer.
Key Financial Metrics and Capital Activities
- Debt Issuance: The Company issued convertible promissory notes with an aggregate principal amount of $755,000, generating cash proceeds of $676,480. These notes bear interest at 12% per annum with maturities between April 2019 and October 2019.
- Debt-for-Equity Swap: The Company issued 531,981 shares of common stock to settle outstanding indebtedness totaling $421,707 (inclusive of accrued interest and fees).
- Stock Issuance for Notes: In connection with $635,000 of the new convertible notes, the Company issued 24,916 shares of common stock to lenders.
- Consulting Note: A $90,000 convertible note was issued for consulting services, bearing 10% interest and maturing in April 2019.
- Liquidity and Margins: The filing text does not provide clear values for revenue, profit, operating margins, or overall liquidity positions beyond the specific cash proceeds noted above.
Material Changes and Corporate Actions
- Capital Structure: Significant dilution occurred through the issuance of 556,897 shares of common stock (24,916 for notes and 531,981 for debt settlement) and the addition of $845,000 in new principal debt obligations ($755,000 cash notes + $90,000 consulting note).
- Management Change: Adam D. Bergstein resigned as Senior Vice President, Planning and Business Development, effective October 28, 2018.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the inherent terms of the new debt instruments. The convertible notes contain significant dilution risks, with conversion prices set at 58% to 65% of the fair market value of the common stock. The Company relied on Section 4(a)(2) and Section 3(a)(9) exemptions of the Securities Act of 1933 for these transactions, asserting that investors were accredited and had access to material information.
Investor Verification Checklist
- Verify the current share count and the impact of the 556,897 newly issued shares on existing ownership percentages.
- Confirm the total outstanding debt load including the new $845,000 in principal and the specific maturity dates (April 2019 to October 2019).
- Assess the potential dilution impact if the 12% and 10% interest-bearing notes are converted at the discounted rates (58% and 65% of fair value).
- Review the Company's cash burn rate to determine if the $676,480 in proceeds is sufficient to meet operational needs until the debt maturities.
- Investigate the strategic implications of the departure of the Senior Vice President of Planning and Business Development.